An approach to using recombinant erythropoietin for neuroprotection in very preterm infants.
Pediatrics. 2008.
PMID: 18676556
Clinical Trial.
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2008 | 1 |
| 2015 | 1 |
| 2024 | 1 |
Search Results
3 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
An approach to using recombinant erythropoietin for neuroprotection in very preterm infants.
Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, Bucher HU.
Fauchère JC, et al.
Pediatrics. 2008 Aug;122(2):375-82. doi: 10.1542/peds.2007-2591.
Pediatrics. 2008.
PMID: 18676556
Clinical Trial.
We investigated whether administration of high-dose recombinant human erythropoietin to very preterm infants shortly after birth and subsequently during the first 2 days is safe in terms of short-term outcome. ...CONCLUSIONS: No significant adverse eff …
We investigated whether administration of high-dose recombinant human erythropoietin to very preterm infants sho …
Item in Clipboard
Neuroprotective potential of erythropoietin in neonates; design of a randomized trial.
Juul SE, Mayock DE, Comstock BA, Heagerty PJ.
Juul SE, et al.
Matern Health Neonatol Perinatol. 2015 Dec 2;1:27. doi: 10.1186/s40748-015-0028-z. eCollection 2015.
Matern Health Neonatol Perinatol. 2015.
PMID: 27057344
Free PMC article.
Review.
New approaches are needed to improve neonatal outcomes. Recombinant erythropoietin (Epo) is a promising neuroprotective agent that is widely available, affordable, and has been used safely in neonates to stimulate erythropoiesis. ...CONCLUSIONS: Epo …
New approaches are needed to improve neonatal outcomes. Recombinant erythropoietin (Epo) is a promising neuroprotect …
Item in Clipboard
Early High-Dose Erythropoietin and Cognitive Functions of School-Aged Children Born Very Preterm.
Wehrle FM, Held U, Disselhoff V, Schnider B, Stöckli A, Toma M, Bucher HU, Fauchère JC, Natalucci G, Hüppi P, Borradori-Tolsa C, Liverani MC, O'Gorman RL, Latal B, Hagmann CF.
Wehrle FM, et al.
JAMA Netw Open. 2024 Sep 3;7(9):e2430043. doi: 10.1001/jamanetworkopen.2024.30043.
JAMA Netw Open. 2024.
PMID: 39254979
Free PMC article.
IMPORTANCE: Children born very preterm are at risk for long-term neurodevelopmental sequelae. Prophylactic high-dose recombinant human erythropoietin (rhEpo) shortly after birth has not been shown to improve cognitive, motor, and behavioral development at 2 a …
IMPORTANCE: Children born very preterm are at risk for long-term neurodevelopmental sequelae. Prophylactic high-dose recombinant …
Item in Clipboard
Cite
Cite